David Hallal - 29 Aug 2025 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Reporting relationship: Director
Issuer ticker: ITOS
Reported as of: 29 Aug 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 29 Aug 2025, 16:30:04 UTC
Prior SEC filing: 06 Jun 2025
Next SEC filing: 09 Oct 2025
Source filing: View source filing
Reporting owner signature: /s/ Adi Osovsky, as Attorney-in-Fact

Key filing fact

David Hallal filed Form 4 for iTeos Therapeutics, Inc. (ITOS) on 29 Aug 2025.

Key facts

This page summarizes David Hallal's Form 4 filing for iTeos Therapeutics, Inc. (ITOS).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 29 Aug 2025, 16:30.

Change

Previous filing in this sequence was filed on 06 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001457477 Primary reporting owner

Hallal David

Relationship: Director
Address: C/O ITEOS THERAPEUTICS, INC., 321 ARSENAL STREET, WATERTOWN
Signature: /s/ Adi Osovsky, as Attorney-in-Fact
Signature date: 29 Aug 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ITOS transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -25,140
Change %: -100%
Price
Shares after: 0
Date: 29 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,140
Exercise price: $2.95
Footnotes: F1, F2

ITOS transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -146,160
Change %: -100%
Price
Shares after: 0
Date: 29 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 146,160
Exercise price: $4.24
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

David Hallal is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the "Company"), Concentra Biosciences LLC ("Parent"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Parent completed a tender offer for shares of common stock of the Company ("Shares") and thereafter, the Merger Sub merged with and into the Company (the "Merger"). In accordance with the terms of the Merger Agreement, at the effective time of the Merger, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company that had an exercise price per share that is less than the $10.047 in cash per share (the "Cash Amount") (each, an "In-the-Money Option") that was then outstanding was canceled and, in exchange therefor,

Footnote F2

(Continued from footnote 1) the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one non-transferable contractual contingent value right for each Share underlying such In-the-Money Option.